BRCA突变上皮性卵巢癌患者及家属因遗传咨询和BRCA检测转诊率低而错失治疗和预防机会:文献综述
约15%的上皮性卵巢癌女性携带遗传性BRCA突变,知晓BRCA状态对患者本人(PARP抑制剂治疗获益)和家属(降低风险手术预防卵巢癌)均有价值。但遗传咨询和BRCA检测的转诊率仅为10%至30%,导致治疗和预防机会被错失。本文综述了BRCA与卵巢癌的关系、转诊率低的原因、改进策略、现有筛查策略的无效性、降低风险手术的利弊、其他预防选择及PARP抑制剂的作用和价值。
要点
- 约15%上皮性卵巢癌女性携带遗传性BRCA突变,PARP抑制剂对携带突变者疗效最大。
- 遗传咨询和BRCA检测转诊率仅10%至30%,治疗和预防机会被错失。
- 降低风险手术可显著降低BRCA突变携带者罹患这种大部分不可治愈癌症的风险。
核心结论
- 尽管BRCA状态对患者治疗和家属预防均有潜在获益,但遗传咨询和BRCA检测转诊率仅为10%至30%,治疗和预防机会正被错失。
研究设计与样本
- 本文为文献综述,作者复习了相关现有文献。
主要发现
- 15%的上皮性卵巢癌女性携带遗传性BRCA乳腺癌易感基因突变。
- 遗传咨询和后续BRCA检测的转诊率为10%至30%。
- PARP抑制剂对携带BRCA突变的女性疗效最大。
- 降低风险手术可显著降低BRCA突变携带者罹患这种大部分不可治愈癌症的机会。
关键数值与推荐
- 15%的上皮性卵巢癌女性携带遗传性BRCA突变。
- 遗传咨询和BRCA检测转诊率为10%至30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Answer questions and earn CME/CNE Fifteen percent of women with epithelial ovarian cancer have inherited mutations in the BRCA breast cancer susceptibility genes. Knowledge of her BRCA status has value both for the woman and for her family. A therapeutic benefit exists for the woman with cancer, because a new family of oral drugs, the poly ADP-ribose polymerase (PARP) inhibitors, has recently been approved, and these drugs have the greatest efficacy in women who carry the mutation. For her family, there is the potential to prevent ovarian cancer in those carrying the mutation by using risk-reducing surgery. Such surgery significantly reduces the chance of developing this, for the most part, incurable cancer. Despite these potential benefits, referral rates for genetic counseling and subsequent BRCA testing are low, ranging from 10% to 30%, indicating that these therapeutic and prevention opportunities are being missed. The authors have reviewed the relevant available literature. Topics discussed are BRCA and its relation to ovarian cancer, the rates of referral for genetic counseling/BRCA testing, reasons for these low rates, potential strategies to improve on those rates, lack of effectiveness of current screening strategies, the pros and cons of risk-reducing surgery, other prevention options, and the role and value of PARP inhibitors. CA Cancer J Clin 2017;67:493-506. © 2017 American Cancer Society.
引用
- Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin. 2017. PMID: 28881380. doi:10.3322/caac.21408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。